Insmed (NASDAQ:INSM) Earns Buy Rating from HC Wainwright

Insmed (NASDAQ:INSM - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $90.00 target price on the biopharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 29.14% from the stock's current price.

INSM has been the subject of several other reports. Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. UBS Group lifted their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Morgan Stanley increased their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Stifel Nicolaus cut their price target on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Stock Performance

Shares of Insmed stock traded up $0.73 during midday trading on Tuesday, hitting $69.69. The company had a trading volume of 13,610,728 shares, compared to its average volume of 2,302,671. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of -12.47 and a beta of 1.07. Insmed has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a fifty day simple moving average of $74.38 and a 200 day simple moving average of $73.53.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the completion of the sale, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. This represents a 2.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 28,390 shares of the stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $2,296,751.00. Following the completion of the sale, the chief financial officer now owns 155,506 shares of the company's stock, valued at approximately $12,580,435.40. The trade was a 15.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 471,797 shares of company stock valued at $37,621,239 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. Jennison Associates LLC grew its holdings in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC purchased a new stake in shares of Insmed during the 4th quarter valued at approximately $586,000. Tidal Investments LLC lifted its holdings in Insmed by 447.0% in the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock valued at $1,759,000 after acquiring an additional 19,696 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Insmed by 237.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after acquiring an additional 41,918 shares during the last quarter. Finally, abrdn plc raised its position in Insmed by 159.5% in the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock valued at $19,998,000 after purchasing an additional 178,041 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.